Stock ABUS ARBUTUS BIOPHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
2.73 USD +0.37% Intraday chart for Arbutus Biopharma Corporation +0.37% +9.20%
04-05 Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit MT
04-04 Moderna Suffers Setback in Lawsuit by Arbutus MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit
Moderna Suffers Setback in Lawsuit by Arbutus
Moderna shares fall after judge sides with Arbutus in patent fight
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD
Arbutus Biopharma Posts Q3 Net Loss, Lower Revenue; CEO to Retire, 24% Research Staff Cut
Arbutus Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Arbutus Biopharma Corporation Announces CEO Changes
Arbutus Biopharma Corporation Announces President Changes
Arbutus Biopharma Discontinues Coronavirus, Oral RNA Destabilizer Programs, Focuses on Hepatitis B Virus Treatment Assets
Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101
Arbutus Biopharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Arbutus Biopharma Corporation Announces the Appointment of Melissa V. Rewolinski to Its Board of Directors
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer
Arbutus Biopharma Corporation Appoints Two New Executives
Arbutus' Phase 2a Trial Shows AB-729 Plus Pegylated Interferon Alfa-2a Well Tolerated in Chronic Hepatitis B Virus Patients
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2A Triple Combination Clinical Trial That Includes A Pd-1 Monoclonal Antibody
Arbutus Presents Preliminary Ab-729 and Pegylated Interferon Alfa-2A Combination Data At the Easl Congress 2023
Arbutus Biopharma Corporation to Present AB-729 and AB-836 Data at EASL Congress 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABUS Stock
  4. News Arbutus Biopharma Corporation
  5. Other languages